A. Bilir Et Al. , "Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro," JOURNAL OF GYNECOLOGIC ONCOLOGY , vol.22, no.4, pp.225-232, 2011
Bilir, A. Et Al. 2011. Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro. JOURNAL OF GYNECOLOGIC ONCOLOGY , vol.22, no.4 , 225-232.
Bilir, A., Erguven, M., Ermis, E., Sencan, M., & YAZIHAN, N., (2011). Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro. JOURNAL OF GYNECOLOGIC ONCOLOGY , vol.22, no.4, 225-232.
Bilir, Ayhan Et Al. "Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro," JOURNAL OF GYNECOLOGIC ONCOLOGY , vol.22, no.4, 225-232, 2011
Bilir, Ayhan Et Al. "Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro." JOURNAL OF GYNECOLOGIC ONCOLOGY , vol.22, no.4, pp.225-232, 2011
Bilir, A. Et Al. (2011) . "Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro." JOURNAL OF GYNECOLOGIC ONCOLOGY , vol.22, no.4, pp.225-232.
@article{article, author={Ayhan Bilir Et Al. }, title={Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro}, journal={JOURNAL OF GYNECOLOGIC ONCOLOGY}, year=2011, pages={225-232} }